By Chris Wack
Insmed shares were up 16% to $26.21, a 52-week high, after the company reported positive topline results from its Phase 3 study of Arikayce.
The study followed patients with newly diagnosed or recurrent nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex.
The…
Read the full article here
